Clinical Trials · NCT02299089

Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)

Name: Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 2Octreotide

Phase: Phase 2
Recruitment status: Completed
Sponsor: Camurus AB
Enrollment: 12
Start date: Jan 2015
Locations: 10 sites, 4 countries
Primary endpoint: Pharmacokinetic (PK) Profile of Octreotide After Each Injection of CAM2029 as Compared With Baseline PK for Sandostatin® Long-acting Release (LAR®) AUC

View Octreotide compound reference